Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the 3SBio’s SSGJ-707.

GSK has secured approval in the European Union (EU) for Blenrep combinations to treat adults with relapsed or refractory multiple myeloma.

Positive topline results of Apnimed's LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.

As clinical trial complexities grow, ICH E6 (R3) updates emphasize smarter monitoring, greater participant focus, and a stronger tech role.

In 2025, Turbine took the first steps in opening its powerful cell simulation platform to the wider drug development ...

The EC has approved Janssen-Cilag International’s new indication for Darzalex Faspro (daratumumab) to treat adults with SMM.

The 2025 Pharmaceutical Technology Excellence Awards are now open for submissions, and you can download our Research Guide for more details.

The UK is the first country to introduce a dedicated law to decentralise manufacturing of personalised medicines at the point of care.

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing and research and development (R&D).

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.